| Note |
Experience. Still your highest authority. The discovery of Librium at Hoffmann-La Roche represented a landmark in psychotherapeutics. And, more specifically, a landmark in the treatment of anxiety and anxiety-related conditions. Today, the acceptance of Librium by the medical community is based firmly on experience. And on a well-documented clinical record. A record so voluminous it had to be put into a computerized storage and retrival system. Take the matter of safety, for example. Experience with millions of patients indicates that the most common side effects of Librium are dose-related and, therefore, largely avoidable. There appears to be a low potential for dependence. Tolerance rarely develops. Few cases of known toxicity have been reported. However, patients should be cautioned about possible combined effects with alcohol and other CNS depressants. Librium seldom produces adverse effects on the cardiovascular or respiratory system. It is used concomitantly with many primary medications, such as cardiac glycosides, antihypertensive agents, anticholinergics, diuretics, anatcids, and anticoagulants. It should be noted that variable effects on blood coagulation have been reported very rarely in patients receiving Librium and oral anticoagulants; however, a causal relationship has not been established clinically. Experience. Yours and ours. Together they make the task of choosing an antianxiety agent much simpler. The anxiety-specific. |
